Literature DB >> 2496332

Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.

P D Lyden1, J A Zivin, W A Clark, K Madden, K C Sasse, V A Mazzarella, R D Terry, G A Press.   

Abstract

Tissue plasminogen activator (tPA) dissolves intravascular thrombus and restores blood flow after thromboembolic vascular occlusion. The utility of this agent for treatment of stroke in humans may be limited by post-reperfusion hemorrhagic complications. We studied tPA-mediated thrombolysis in an animal model of cerebrovascular occlusion in order to determine what factors, if any, predispose tPA-treated animals to suffer hemorrhage. Small blood clot emboli were injected into the internal carotid arteries of rabbits. Angiograms confirmed occlusion of the middle cerebral artery or internal carotid artery in 100% of subjects. tPA or saline was administered as a 30-minute infusion at various times after embolization. Hemorrhage rates were similar in all groups regardless of treatment. tPA increased the prothrombin time and the thrombin time but not the partial thromboplastin time. There was no correlation between these changes in blood coagulation and the finding of cerebral hemorrhage. We observed a significant association between stroke severity and cerebral hemorrhage. We conclude that tPA treatment successfully causes thrombolysis of cerebral emboli without causing an increase in the incidence of cerebral hemorrhage in rabbits.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496332     DOI: 10.1212/wnl.39.5.703

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

2.  A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2015-02-01       Impact factor: 6.829

3.  A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits.

Authors:  Paul A Lapchak
Journal:  Brain Res       Date:  2010-06-21       Impact factor: 3.252

Review 4.  Thrombolytic therapy for stroke: a review with particular reference to elderly patients.

Authors:  K W Muir; M Roberts
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 5.  Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.

Authors:  L Candelise; C Roncaglioni; E Aritzu; A Ciccone; A P Maggioni
Journal:  Ital J Neurol Sci       Date:  1996-02

Review 6.  Thrombolysis in acute ischaemic stroke.

Authors:  A C Pereira; P J Martin; E A Warburton
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

7.  Thrombolytic Therapy for Acute Ischemic Stroke.

Authors:  Patrick D Lyden
Journal:  Stroke       Date:  2019-07-22       Impact factor: 7.914

8.  A blinded, randomized study of L-arginine in small clot embolized rabbits.

Authors:  Paul A Lapchak; Jessica T Daley; Paul D Boitano
Journal:  Exp Neurol       Date:  2015-02-20       Impact factor: 5.330

9.  Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model.

Authors:  Aliza T Brown; Rene Flores; Eric Hamilton; Paula K Roberson; Michael J Borrelli; William C Culp
Journal:  Invest Radiol       Date:  2011-03       Impact factor: 6.016

Review 10.  Evolution of the thrombolytic treatment window for acute ischemic stroke.

Authors:  Andrew Stemer; Patrick Lyden
Journal:  Curr Neurol Neurosci Rep       Date:  2010-01       Impact factor: 5.081

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.